Pharma Marketing News
News & Views for
Responsible Marketers

Messages from Our Sponsors

Pharma Glossary

Pharmaguy's Picks

Pharma Marketing Network Curated Content Forums
The Leading Online Source of Curated Content for Pharmaceutical Marketing Experts
Newsletter | Conferences | Podcasts | Glossary | Surveys | Blog | Advertising Information | Contact Us

"Must Read Blog for Insiders." -- Wall Street Journal
Pharma Marketing News
Current Issue of Pharma Marketing News Available!

Search the Entire Pharma Marketing Forums Site

Go Back   Pharma Marketing Network Curated Content > News & Views > Industry News

Industry News Pharmaceutical industry news from newsfeeds, press releases, news stories, etc.

Thread Tools Rate Thread Display Modes
Old 17th January 2011, 02:13 PM
Pharma Newshound Pharma Newshound is offline
News Gatherer
Join Date: Dec 2007
Location: USA
Posts: 11,038
Default GSK takes record £2.2bn charge


GlaxoSmithKline has unveiled a record-breaking £2.2bn ($3.5bn) charge to settle product liability lawsuits and regulatory fines linked to past sales practices by the UK-based pharmaceutical company in the US.

The fourth-quarter provision, which the company said would be reduced to £1.8bn after tax deductions, outstrips the previous largest settlement imposed on a pharmaceuticals company, when Pfizer paid $2.3bn to US regulators last year.

GSK’s latest charge comes amid a series of escalating legal actions launched against drug companies in the US by regulators and patients over allegations of aggressive marketing and side-effects caused by medicines.

It relates to sales practices and ill-health linked to different drugs, is the company’s best estimate of the size of the settlements that it will ultimately pay, but the total could still increase.

GSK would not split out the precise breakdown of the £2.2bn figure, but the bulk of it relates to the estimated settlement from an investigation led by the US attorney’s office for the District of Colorado for US sales and promotional practices between 1997 and 2004, including for its anti-depressant treatments Paxil and Wellbutrin.

Such probes typically focus on “off-label” promotion by drug companies to doctors of their medicines for uses beyond the official “label” of indications that have been formally approved by the US Food and Drug Administration.

The charge also includes an unspecified amount to cover continuing product litigation claims by patients linked to Avandia, GSK’s former blockbuster diabetes drug that was all but withdrawn in the US and Europe late last year after concerns about cardiovascular side-effects.

It comes as Andrew Witty, the chief executive appointed in 2008, moves to bring to an end protracted investigations around drug company activities in the past as he attempts to champion a more ethical approach to business.

Last edited by Pharma Newshound : 17th January 2011 at 02:17 PM.
Reply With Quote

Thread Tools
Display Modes Rate This Thread
Rate This Thread:

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is On
Forum Jump

All times are GMT -5. The time now is 07:52 PM.

Powered by vBulletin® Version 3.6.4
Copyright ©2000 - 2014, Jelsoft Enterprises Ltd.
(c) 2014, Pharma Marketing Network. All rights reserved.